In a study published in Molecular Therapy, researchers from H. Lee Moffitt Cancer Center and Research Institute and the University of South Florida developed an E6-targeting proteolysis targeting chimera (PROTAC) that inhibits the growth of human papillomavirus (HPV)-positive tumors. HPV is the most prevalent sexually transmitted infection worldwide, with persistent infections causing up to six different types of cancer.
Abion Inc. has presented data for ABN-202, a hyperglycosylated interferon (IFN) β mutein fused to a monoclonal antibody targeting tumor-associated calcium signal transducer 2 (TROP2) that retains activity under acidic conditions.
CCNK is frequently upregulated in diverse tumor types, where its increased expression promotes proliferation and its depletion triggers apoptosis. Researchers from Guangdong Pharmaceutical University reported the discovery and preclinical characterization of a novel series of CCNK molecular glue degraders with antitumor activity.
Australian researchers have found a drug combination that can bypass the cellular defenses in neuroblastoma that lead to relapse, and the discovery could lead to better treatment strategies for children whose cancers have stopped responding to standard chemotherapy.
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged cyclin-dependent kinase 2 (CDK2) and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of inflammatory disorders, immunological disorders and cancer.
Chengdu Chipscreen Pharmaceutical Ltd. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Abbisko Therapeutics Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.
Triple-negative breast cancer (TNBC) is a highly aggressive subtype affecting 15%-20% of breast cancer patients. TNBC patients harboring breast cancer susceptibility gene 1/2 (BRCA1/2) mutations have shown improved therapeutic response to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi).
T cell-engaging bispecific antibodies (TCEs) are engineered molecules designed to bring cytotoxic T cells into proximity with tumor cells, triggering a targeted, antigen-dependent immune attack. However, TCE may activate T cells in healthy tissues, leading to off-tumor toxicity.
G1 to S phase transition 1 (GSPT1) is a protein involved in cell cycle progression, translation termination, and protein homeostasis, and its overexpression has been implicated in various cancers. Although GSPT1 is considered a promising therapeutic target, the lack of conventional ligand-binding pockets has historically rendered it undruggable.
RSS
